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Abstract
Patients with cancer represent a growing group among actual ICU admissions (up to 20 %). Due to their increased
susceptibility to infectious and noninfectious complications related to the underlying cancer itself or its treatment,
these patients frequently develop acute kidney injury (AKI). A wide variety of definitions for AKI are still used in the
cancer literature, despite existing guidelines on definitions and staging of AKI. Alternative diagnostic investigations
such as Cystatin C and urinary biomarkers are discussed briefly. This review summarizes the literature between 2010
and 2015 on epidemiology and prognosis of AKI in this population. Overall, the causes of AKI in the setting of
malignancy are similar to those in other clinical settings, including preexisting chronic kidney disease. In addition,
nephrotoxicity induced by the anticancer treatments including the more recently introduced targeted therapies is
increasingly observed. However, data are sometimes difficult to interpret because they are often presented from
the oncological rather than from the nephrological point of view. Because the development of the acute tumor
lysis syndrome is one of the major causes of AKI in patients with a high tumor burden or a high cell turnover, the
diagnosis, risk factors, and preventive measures of the syndrome will be discussed. Finally, we will briefly discuss
renal replacement therapy modalities and the emergence of chronic kidney disease in the growing subgroup of
critically ill post-AKI survivors.
Background
The association between cancer and kidney disease has
long been recognized but received extra attention after
the creation of a ‘new’ nephrological subspecialty, called
‘onco-nephrology’ [1].
Over the past several years, important advances have
occurred in the treatment and supportive care of pa-
tients with malignancies. Given the increasing number
of novel therapeutics and the complexity of cancer treat-
ment protocols, nephrologists and intensivists face the
difficult task to stay updated on the advances in onco-
nephrology.
Acute kidney injury (AKI) and electrolyte disturbances
are the most common forms of renal disease that occur
in a patient with cancer [2]. As in practically all other
causes of AKI, preexisting chronic kidney disease is one
of the most important predisposing risk factors, next to
extracellular volume depletion due to vomiting or diar-
rhea, urinary tract obstruction, fluid and electrolyte
disturbances, exposure to contrast media, nephrotoxic
antibiotics, nonsteroidal anti-inflammatory drugs, and
nephrotoxicity induced by some of the anticancer treat-
ments [2]. During recent years, a great number of so-
called targeted therapies have been introduced, but
unfortunately many of these drugs have renal side
effects, AKI being one of them [3, 4].
Cancer patients are particularly at risk for AKI secondary
to infection and sepsis [5, 6], tumor lysis syndrome (TLS)
[7], kidney damage induced by immunosuppression after
hematopoietic stem cell transplantation (HSCT) [8], and
direct effects from the primary malignancy [9].
The development of AKI can jeopardize further cancer
treatment, increase the toxicity and/or reduce the
delivery of chemotherapy, and exclude patients from
clinical trials.
The incidence and severity of AKI varies depending on
the type and stage of cancer, treatment course, and co-
morbidities [10–12]. As in other clinical settings, AKI
morbidity and mortality increase in the presence of
critical illness or the need for renal replacement therapy
(RRT) [10].
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Most studies of AKI in cancer patients focus on the
relation between hemato-oncological malignancies and
the kidney [13], especially in specific conditions such as
multiple myeloma (MM) [14] and HSCT [15]. However,
only few studies focused specifically on the vast group of
nonhematologic critically ill cancer patients with AKI [16].
This narrative review aims to provide an update on
the relation between AKI and the critically ill cancer pa-
tient. Literature from the last 5 years (between 2010 and
2015) is covered and the article represents a follow-up
of a previously published review on this topic [10].
Diagnosis of AKI in cancer patients
Because the incidence of AKI depends on its definition,
comparisons are most reliable if based on studies using
a more or less uniform definition, as in the Risk, Injury,
Failure, Loss, End stage renal disease (RIFLE), Acute
Kidney Injury Network (AKIN), and Kidney Diseases
Improving Global Outcomes (KDIGO) classifications
(for review see [17]). The KDIGO criteria stage patients
according to changes in serum creatinine (SCr) and
urine output (UO) rather than changes in glomerular
filtration rates (GFR). Both SCr and UO criteria are
important predictors, and use of the KDIGO definition
without assessment of UO underestimates the incidence
and grade of AKI and can delay diagnosis [18].
Patients with cancer often have decreased creatinine
production secondary to loss of cell mass, low protein
intake, cachexia, inflammation, volume expansion, or
medications. All these affect SCr independent of renal
function, and thus limit the sensitivity of creatinine as a
marker of kidney injury. Therefore, a fixed (arbitrary)
level of SCr as a marker of AKI (i.e., >1.5 or 2.0 mg/dl)
is inadequate as affected patients may be overlooked.
Cystatin C
Cystatin C (CysC) is a 13-kDa cystein protease inhibitor
produced in all nucleated cells at a relatively constant
level and is filtered freely by glomeruli and is neither
secreted nor reabsorbed by renal tubules but undergoes
almost complete catabolism by proximal tubular cells.
With a half-life of about 2 hours, serum CysC reflects
GFR better than creatinine. CysC is relatively stable, and
can be accurately measured with automatic analyzers,
although at manifold the cost of SCr.
In a meta-analysis of 13 studies across different set-
tings, including ICU patients, the likelihood ratio for
serum CysC level to predict AKI was 23.5 (95 % CI,
14.2–38.9), with sensitivity and specificity of 0.84 and
0.82, respectively. The area under the receiver operating
characteristic curve (AUROC) of serum CysC level to
predict AKI was 0.96 (95 % CI, 0.95–0.97). Subgroup
analysis showed that serum CysC was of diagnostic value
when measured early (within 24 hours after renal insult
or ICU admission) [19].
In the past, the value and usefulness of CysC in cancer
patients were doubtful, because concentrations were
thought to be influenced by the extent of malignancy.
More recent studies have now found no correlation be-
tween serum CysC concentration and tumor burden [20].
It is important to note that the diagnostic and prog-
nostic characteristics of CysC for AKI remain incom-
pletely defined; not only anthropometric parameters
(age, obesity), but current cigarette smoking, CRP levels,
use of corticosteroids, and changes in thyroid function are
associated with higher serum CysC levels, independent
from GFR. This suggests that serum CysC is a marker of
inflammation as well as of renal function [21].
Novel biomarkers
Because traditional markers like SCr, UO, and CysC are
considered insensitive markers of renal injury, extensive
efforts were spent over the last 15 years to identify and
validate novel biomarkers that are more sensitive for
onset of injury, specific for prediction, and with greater
discrimination for injury severity (for recent in-depth
reviews see [22]).
Essentially three types of novel biomarkers in the field
of AKI have been developed; the first group are
inflammatory biomarkers, including neutrophil gelatinase-
associated lipocalin (NGAL) and proinflammatory cyto-
kines, like IL-6 and IL-18; the second group includes cell
injury biomarkers such as kidney injury molecule-1
(KIM-1), liver fatty acid binding protein (L-FABP),
sodium/hydrogen exchanger 3 (NHE-3), and netrin 1; and
the third group has recently been developed and consists
of cell cycle markers, like urinary tissue inhibitor of
metalloproteinases-2 (TIMP-2) and insulin like growth
factor-binding protein 7 (IGFBP-7).
Probably the most promising application of these bio-
markers in oncology is their potential for early detection
of nephrotoxicity by antineoplastic agents during their
development phase and in preclinical studies. Some
studies [23, 24] have demonstrated that the presence of
antineoplastic nephrotoxicity was associated with an
increase in AKI biomarkers.
Two commercially available AKI biomarkers NGAL
and [TIMP-2]•[IGFBP7] can be measured on standard
platforms used for routine biochemistry or with a point-
of-care device.
Recent findings, however, challenge the robustness and
utility of cell cycle arrest biomarkers for the prediction
of AKI in general ICU patients with heterogeneous diag-
noses, differing comorbidities, and multiple sources of
inflammation [25]. In particular, the association with in-
flammation may obscure the picture in cancer patients.
There are at present no studies that have evaluated
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whether earlier diagnosis of AKI by these biomarkers
indeed results in better patient outcomes, and conse-
quently in decreased costs [26].
Patients with cancer and AKI
A substantial rise in AKI has been noted worldwide [27]
and in the subgroup of noncritically ill and critically ill
patients with cancer [28, 29].
Cancer patients represent about 20 % of ICU admis-
sions [30, 31]. In a recent multinational study, an even
distribution in cancer patients was observed between the
subgroup without (18.8 %) vs with (20.5 %) AKI [30]. As
in many other AKI populations, even small increases of
SCr (0.2 mg/dl–17.6 μmol/l), previously considered
trivial, are associated with prolonged ICU stay and
increased mortality [32], and this is independent from
severity of illness or other risk factors.
In the Dutch National Intensive Care Evaluation
(NICE) database [33] AKI occurred in 19.4 % of hema-
tological patients admitted to the ICU, which is compar-
able with incidence rates in patients with chronic liver
cirrhosis and chronic heart failure, but higher than in
patients with solid tumors (11 %).
Overall prognosis of critically ill cancer patients
The overall prognosis of patients with cancer is strongly
dependent on the type of ICU admission and underlying
cancer. In a cohort including 1257 patients with cancer,
in those admitted to the ICU (404, 32.1 %) overall ICU
and hospital mortalities were 20.8 % and 28.6 %, res-
pectively [34]. As expected, hospital mortality was sig-
nificantly higher for medical (69.4 %) and emergency
surgical patients (49.3 %) than for scheduled surgical
patients (5.7 %; p < 0.001). After exclusion of scheduled
surgical patients, those with solid tumors had a lower
mortality compared with those with hematological
malignancies (56.0 % and 67.2 %, p = 0.030).
Of the 3147 patients enrolled in the SOAP study, 473
(15 %) had a malignancy, 404 (85 %) solid cancer, and 69
(15 %) hematological cancer [35]. Patients with solid
cancers had a similar severity of illness compared with
the noncancer population, but cancer patients were
older and were more likely to be admitted after surgery.
Patients with hematological malignancies were the most
severely ill and more commonly suffered from sepsis,
acute lung injury/acute respiratory distress syndrome,
and renal failure than patients with other malignancies;
these patients also had the highest hospital mortality
rate (58 %). The outcome of all cancer patients was
comparable with that of the noncancer population, with
a 27 % hospital mortality rate. However, in the subset of
patients with more than three failing organs, greater
than 75 % of patients with cancer died compared with
about 50 % of patients without cancer (p = 0.01).
Similar results were obtained in the Dutch NICE data-
base [33]. ICU (33.8 %) and hospital (47.4 %) mortalities
were higher in hematological compared with nonhema-
tological patients (17.9 % and 26.3 %, respectively).
Important, however, is that 60-day mortality in patients
with hematological malignancies and solid cancer was
similar to patients with other classical severe comorbidities,
and in the ranges of those for critically ill hematological
patients in ICUs in France and Belgium [36].
Overall mortality has sharply dropped among ICU pa-
tients with hematological malignancies, including those
requiring mechanical ventilation [37]. However, whether
this improvement is due to better ICU triage or to real
improvements in supportive therapy is unclear [38].
Epidemiology and prognosis of AKI in critically ill
cancer patients
AKI requiring RRT is more common in ICU patients
with vs without cancer [9]. Hospital mortality rates are
high in cancer patients with AKI, especially when RRT is
required [9, 16].
The multiple types of renal injury that may precede or
are concurrent with critical illness make cancer patients
particularly vulnerable to the development of AKI, which
therefore frequently occurs in the setting of multiple
organ dysfunction.
Table 1 summarizes studies over the last 5 years on
epidemiology of AKI in adult critically ill cancer patients
admitted to the ICU. The table contains data on the type
of study (monocentric or multicentric), type of cancer
(hemato-oncology or solid tumors), reasons for admis-
sion to the ICU, applied definition of AKI, calculated
incidence of AKI, causes or contributing factors to the
AKI, survival data, indications and type of RRT, and
where possible some long-term effects of AKI on patient
health.
The table contains 15 publications of which only five are
multicentric [30, 33, 39–41]. Eight studies consider all can-
cers (solid and hematologic) [6, 30, 32, 33, 40, 42–44]; the
rest consider only hematologic tumors [11, 39, 41, 45–48].
AKI is not always clearly defined and only eight studies use
the RIFLE, AKIN, or KDIGO classifications [11, 30, 32, 39,
40, 44, 46, 47], usually only taking into account SCr and
not urinary volume. It is highly probable that in some
papers the need for RRT was used as definition of
AKI [6, 40, 42, 45, 48], which creates a risk of under-
estimation of AKI incidence, at least in part explaining the
variability in different reports. Furthermore, the incidence
of AKI on admission was sometimes lower than the num-
ber of patients in whom RRT treatment was needed after
admission, suggesting that AKI very frequently develops
during the ICU stay [43, 45]. Many studies start from the
oncologic viewpoint and consider AKI as one of the many
determinants of outcome, not considering specific aspects
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Table 1 Summary of publications between 2010 and 2015 on critically ill cancer patients with AKI
Reference Multicenter
(Yes/No)
Type of
cancer
Population Reasons for
admission
to ICU
Definition of AKI Incidence of
AKI
Cause(s) of AKI/
contributing
factors
Survival/mortality
of AKI cancer
patients (%)
Survival/
mortality of
non-AKI cancer
patients (%)
Indications for
RRT
RRT
modality
Long-term
prognosis
for AKI
patients
[46] No Hemato 537 with
induction
chemo
- 50 % rise in SCr
above baseline
RIFLE
36 %
RIFLE
R: 15 %
I: 10 %
F: 11 %
? Mortality
RIFLE
R: 13.6 %
I: 19.6 %
F: 61.7 %
Mortality: 4 % Indications?
RRT: 8 %
?
[48] No Hemato 344 Infections/
noninfectious
complications
? 16.6 % ? ? ? ?
[47] No Hemato 94 Severe sepsis/
shock: 71 %
Renal failure:
17 %
Respiratory
failure: 12 %
Need for RRT
RIFLE
RIFLE
R:7 %
I: 33 %
F: 60 %
Septic AKI:
54 %
Nonseptic
AKI: 46 %
Nephrotoxic
drugs: 15/94
Hypovolemic:
13/94
TLS: 11/94
23.5 % survival - CVVHDF/
CVVHF
23 % of
survivors
persistent
AKI after ICU
discharge
[32] No All 3795
medical/
surgical pts
Oncology ICU
Not specified
Assess link to
outcome of
increases of SCr
cfr RIFLE
21.8 %
RIFLE
R: 12.5 %
I: 4.9 %
F: 4.5 %
Multiple Creat rise: 10 %:
Mortality:
15–25 %;
Creat rise 25 %:
? ?
RRT: 19 % in
nonsurvivors,
1.6 % in
survivors
? ?
Mortality:
14–30 %
Rise in SCr of
25 % (≥48 h)
Mortality: 36 %
No rise in SCr
of 25 % for
≥ 48 h:
Mortality: 15 %
[40] Yes All All AKI 773 pts
Ca pts:
118 (15.2 %)
Solid cancer:
73 %
Hemato:
27 %
Serious
comorbidities
RIFLE before start
of RRT
118/773
100 % AKI
RIFLE
R: 25 %
I: 24 %
F: 52 %
Sepsis: 78 %
Ischemia/shock:
74 %
Toxins/contrast:
32 %
Ca pts hospital
survival: 12 %
of all survivors
Non Ca pts
hospital survival:
7 % of all survivors
Overall survival:
30 %
- Azotemia:
58 %
Fluid overload:
55 %
Acidosis: 48 %
CRRT:
89 %
?
[45] No Hemato 199 pts onco Oncology ICU
Respiratory
failure: 33 %
Postoperative:
20 %
Sepsis: 21.1 %
?
Need for RRT?
8 % on ICU
admission
? RRT survivors:
38 %
RRT nonsurvivors:
62 %
? 79 (40.9 %) ? ?
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Table 1 Summary of publications between 2010 and 2015 on critically ill cancer patients with AKI (Continued)
[44] No All 477 ca pts ICU surgical
pts
AKIN criteria 10.3 %
on ICU
admission
Post surgery Hospital mortality:
13 %
ICU mortality:
10.9 %
Hosp mortality:
1.5 %
ICU mortality:
1 %
? ? ?
[6] No All 563 ca pts
with sepsis
Solid cancer:
77 %
Hemato:
23 %
Sepsis ?
Need for RRT?
20 % on RRT Sepsis ?
Overall mortality:
ICU: 51 %
Hospital: 65 %
6 month: 72 %
? ? ? ?
[11] No Hemato 200 pts Start chemo
1 day before
ICU
See [73]
RIFLE Total:68.5 %
RIFLE
R: 27 %
I: 19.7 %
F: 53.3 %
Prerenal: 48.2 %
TLS: 43.8 %
ATN: 28.5 %
Nephrotoxicity:
20.4 %
Multiple causes:
45.3 %
ICU mortality:
35 %
Hospital mortality:
35 %
ICU mortality:
7.9 %
Hospital
mortality:
19.1 %
?
52.7 % RRT
(during ICU)
IHD:
63.8 %
CRRT:
19.4 %
Both:
16.6 %
Complete
hemato
remission
At 6 months
AKI: 39.4 %
Non AKI:
68.3 %
[42] No All 162 ca pts
Solid cancer:
104
Hemato:
35.8 %
Septic shock:
66.7 %
Respiratory
failure: 63.6 %
?
Need for RRT?
AKI: 30 %
Hemato:
41 %
Solid cancer:
23 %
? Mortality
AKI:26 %
Total RRT: 33 %
Hemato: 38 %
Solid cancer:
30 %
? ?
[43] No All 56 pts with
chemo
Chemo ? 16 %
Hospital
nonsurvivors:
13 %
Hospital
survivors:
18 %
? ? 39 % CVVHF ?
[33] Yes All Hemato:
1741
Solid tumors:
602
Not specified ? Hemato:
20 %
Solid cancer:
11 %
? ? ?
[30] Yes All Ca pts: 357
(19.8 % of all
admissions)
AKI-EPI study
Multiple KDIGO 59 % ? ? ? ? ? ?
[41] Yes Hemato Neutropenic
pts: 289
Sepsis: 80 %
Acute
respiratory
failure: 64 %
Shock: 58 %
?
Need for RRT?
18 % ? 19.85 % mortality ? ? ? ?
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Table 1 Summary of publications between 2010 and 2015 on critically ill cancer patients with AKI (Continued)
[39] Yes Hemato Hemato: 1009 Acute
respiratory
failure: 62.4 %
Shock: 42.4 %
AKI: 30.5 %
Coma: 22.3 %
Urgent
chemo: 6.9 %
AKIN During ICU
stay: 66.5 %
AKIN1:
38.4 %
AKIN2:
11.2 %
AKIN3:
50.4 %
Nephrotoxic
agents:25.3 %
Sepsis/shock:
31.3 %
Hospital mortality:
44.3 %
AKIN stage
dependent
Hospital
mortality:
25.4 %
RRT: 271 (26.9 %)
RRT-AKIN
AKIN1:
19.6 %
AKIN2:
9.9 %
AKIN3:
64.2 %
CRRT:
136 pts
IHD:
135 pts
12.9 % of
survivors
RRT
dependent
AKI acute kidney injury, AKIN Acute Kidney Injury Network, ca pts cancer patients, chemo chemotherapy, CRRT, continuous renal replacement therapy, CVVHDF continuous venovenous hemodiafiltration, CVVHF continuous
venovenous hemofiltration, hemato hematology, IHD intermittent hemodialysis, KDIGO and Kidney Diseases Improving Global Outcomes, onco oncology, pts patients, RIFLE Risk, Injury, Failure, Loss, End stage renal disease,
RRT renal replacement therapy, SCr serum creatinine, TLS tumor lysis syndrome, ATN acute tubular necrosis
Lam
eire
et
al.CriticalCare
 (2016) 20:209 
Page
6
of
12
related to AKI or a comparison with patients without
AKI. Vice versa, studies concentrating on the AKI aspect
rarely contain a comparison with subjects without cancer.
The picture that arises is one of a population which is ex-
tremely vulnerable to AKI with up to 60 % of patients de-
veloping AKI [11, 39], and up to 40 % of them in need of
RRT [43, 45]. Main causes associated with AKI are sepsis
and septic shock [6, 39, 40, 42, 47], tumor lysis [11, 39, 43],
and nephrotoxic agents [11, 39, 46].
Figure 1 illustrates the different major risk factors of
AKI in 1009 critically ill cancer patients with (n = 671)
and without (n = 338) AKI, taken from the recent paper
by Darmon et al. [39]. Although many risk factors were
present in both patient groups, severe sepsis, a history of
hypertension, exposure to nephrotoxic agents, preexis-
tent chronic kidney disease, and TLS were significantly
more frequent in the AKI patients.
Length of stay in the ICU is, in general, longer for
cancer patients with AKI than for those without AKI
[11, 32], but in one study the stay was not longer than
for noncancer patients with AKI [40]. Length of hospital
stay, if mentioned, is the same in AKI patients with and
without cancer [11, 40, 44]. In one study [11], AKI pa-
tients showed less complete remission of the malignancy
(39.4 %) compared with patients without AKI (68.3 % re-
mission). Long-term kidney function is rarely mentioned
and appears not to recover in all cases; 23 % [47] or
12.9 % [39] of surviving hematologic patients needed
RRT after ICU discharge. AKI patients with cancer have
a higher mortality than those without cancer [6, 40],
cancer patients with AKI have a higher mortality than
those without AKI [11, 32, 39, 46], RRT is linked to an
even higher mortality [39, 41–43], and mortality in-
creases with severity of AKI [32, 46].
In future studies, potential attention points could be:
the use of now generally accepted classification systems
like RIFLE, AKIN, or preferably KDIGO; indications of
RRT and length of ICU and hospital stay; comparisons
of AKI vs no AKI in studies focusing on cancer, and of
cancer vs no cancer in studies focusing on AKI; and
long-term kidney function, and long-term survival and
response to chemotherapy of cancer patients with AKI.
Prevention of AKI in critically ill cancer patients
It is beyond the scope of this review to discuss the gen-
eral prevention of AKI in critically ill patients. Recent
comprehensive literature on this topic is available [17].
A specific cause of potentially dramatic AKI – acute
TLS – requires the attention of all stakeholders; the
hemato-oncologist, the nephrologist, and the intensivist.
Tumor lysis syndrome
TLS is an oncologic emergency caused by the release of
large amounts of potassium, phosphate, and nucleic
acids into the systemic circulation secondary to massive
tumor cell lysis and may lead to life-threatening AKI, ar-
rhythmias, and neurologic complications. TLS typically
occurs after the initiation of anticancer therapies, includ-
ing cytotoxic drugs, biological agents, corticosteroids,
hormones, and radiation therapy. TLS has been reported
with virtually every type of tumor, but is typically associ-
ated with bulky, chemosensitive hematologic malig-
nancies. The incidence of TLS in patients with solid
malignancies may be higher than previously thought
[49]. TLS may also arise spontaneously as a consequence
of increased tumor cell lysis before any definitive
antitumor therapy has been initiated (for recent reviews
see [7, 50]). The 2004 Cairo and Bishop classification
Fig. 1 Factors associated with AKI in hemato-oncology patients. Adapted from Darmon et al. [39]. *p < 0.05. AKI acute kidney injury
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system for TLS made a distinction between laboratory
TLS and clinical TLS, the latter defined as laboratory
TLS accompanied by symptomatic complications, and
was revised in 2010 [51]. However, the distinction be-
tween clinically relevant and laboratory defined TLS re-
mains difficult and the Cairo and Bishop classification is
therefore not uniformally accepted [50].
AKI in TLS is usually oliguric and has various mecha-
nisms; most commonly, the deposition of uric acid
crystals in distal tubules resulting in intraluminal ob-
struction is the main pathogenetic factor. Other pos-
sibilities are precipitation of calcium phosphate, renal
infiltrates of tumor, tumor-related obstructive uropathy,
drug-induced nephrotoxicity, preexisting renal impair-
ment, dehydration, and sepsis.
Risk assessment of TLS
General risk factors are common to most forms of AKI,
like patient’s age and intravascular volume status, expos-
ure to potentially nephrotoxic substances, and baseline
kidney function. Certain intrinsic tumor-related risk
factors include, among others, a high tumor cell prolifer-
ation rate, the degree of chemosensitivity of the malig-
nancy, and the presence of a bulky disease >10 cm in
diameter and/or a white blood cell count >50,000/μl.
Certain biochemical parameters such as pretreatment
serum lactate dehydrogenase (LDH) more than two
times the upper limit of normal, pretreatment hyper-
uricemia (serum uric acid >7.5 mg/dl (>446 μmol/l)) or
hyperphosphatemia and an abnormal SCr [50] are
additional risk factors for TLS.
Subjects at intermediate and high risk of TLS should
be monitored in a hospital setting and possibly in an
ICU (especially individuals at high risk of TLS).
Prevention of TLS
All patients who are at risk for the TLS should receive
intravenous hydration to rapidly improve renal perfusion
and glomerular filtration and to minimize acidosis and
oliguria (an ominous sign). Hydration is realized by
means of intravenous fluids (2500–3000 ml/m2 per day
of preferably isotonic saline). Diuretics do not have a
proven role in reducing the incidence or severity of TLS
and their routine use is not recommended unless there
are clinical signs or symptoms of volume overload [52].
The role of urinary alkalinization is unclear and contro-
versial; no controlled human studies exist to inform the
decision of whether to attempt alkalinization. Although
alkalinization improves urate solubility, a high pH de-
creases the solubility of xanthine, hypoxanthine, and cal-
cium phosphate, potentially increasing the likelihood of
intratubular crystallization. If alkalinization is used in
this setting, serum phosphorus should be followed care-
fully and should be stopped when hyperphosphatemia
develops, to minimize the risk of acute phosphate
nephropathy [53].
Allopurinol and rasburicase, a recombinant urate oxi-
dase preparation, decrease the synthesis of uric acid in
patients with rapidly growing tumors who are prone to
uric acid nephropathy and TLS [50]. Allopurinol should
be started at least 24–48 h prior to chemotherapy or ra-
diation therapy to reduce the risk of uric acid nephropa-
thy. Although allopurinol prevents the formation of uric
acid, existing uric acid must still be excreted. The level
of uric acid may take 2 days or more to decrease, a delay
that allows urate nephropathy to develop. Despite
treatment with allopurinol, xanthine may accumulate,
resulting in xanthine nephropathy. Patients who do not
tolerate oral medication can be given allopurinol intra-
venously. The recommended dose of allopurinol is up to
800 mg/day orally or 300 mg/m2, and up to 600 mg/day
for the intravenous formulation [54]. The dose of allo-
purinol should be reduced in the presence of chronic
kidney disease.
Febuxostat is a xanthine oxidase inhibitor that does
not have the hypersensitivity profile of allopurinol and
does not require dosing adjustments for reduced GFR.
Like allopurinol, febuxostat is not expected to decrease
the accumulation of xanthine or the risk for xanthine
stone formation. Febuxostat may be a reasonable, albeit
expensive, alternative to allopurinol in the prophylaxis of
TLS in patients with decreased estimated GFR [52].
Rasburicase is a recombinant form of Aspergillus-
derived urate oxidase and catalyzes the oxidation of uric
acid to allantoin, which is 5–10 times more soluble than
uric acid and is readily excreted. Rasburicase was
approved by the US Food and Drug Administration (FDA)
for children in 2002 and adults in 2009. The US FDA-
recommended dosing guideline for rasburicase in pedia-
tric patients is 0.15 mg/kg or 0.2 mg/kg administered once
daily for a maximum of 5 days. Treatment beyond 5 days
or for more than one course of therapy is not re-
commended. The first dose of rasburicase should be
administered 4–24 hours before starting chemotherapy.
Rasburicase is given as an intravenous infusion over
30 minutes and should not be given as a bolus infusion.
Currently, in the adult population, the dose often utilized
in practice is 0.2 mg/kg. Rasburicase is now a standard of
care for patients at high risk of TLS despite continuing
debate on whether its profound and rapid lowering of
plasma uric acid levels translates into hard patient out-
comes (e.g., AKI with a need for RRT or mortality). Two
recent meta-analyses [55, 56] concluded that the mor-
tality and cost-effectiveness benefits of this expensive
drug remain to be proven. Several studies have reported
higher rates of serious adverse reactions (pulmonary
hemorrhage, respiratory failure, supraventricular ar-
rhythmias, ischemic coronary artery disorders, and
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abdominal and gastrointestinal infections) with rasburi-
case compared with allopurinol [57].
The liberation of hydrogen peroxide induced by
rasburicase can be devastating in patients with glucose
6-phosphate dehydrogenase (G6PD) deficiency, an ab-
normality affecting 400 million people worldwide, especially
in regions with endemic malaria [58]. In these individuals
the unchecked oxidative potential of hydrogen peroxide can
lead to methemoglobinemia and hemolytic anemia [59].
Particularly in patients of African, Mediterranean, or
Southeast Asian ancestry, testing for G6PD deficiency is
warranted before the administration of potent oxidizing
agents (e.g., rasburicase).
Acute phosphate AKI can also be part of TLS and it
has been suggested that wide use of rasburicase and
urine alkalinization has resulted in a paradigm shift to-
wards acute phosphate nephropathy in TLS-induced
AKI [60]. TLS patients may develop a first episode of
AKI secondary to spontaneous TLS-induced acute urate
nephropathy, treated with rasburicase and allopurinol,
and a second episode due to chemotherapy-induced TLS
with acute phosphate nephropathy.
Established TLS
Several features of the preventive management of TLS
remain the mainstay also for the treatment of established
TLS. RRT should be considered for all critically ill pa-
tients with TLS having persistent metabolic abnormal-
ities or renal failure in spite of fluid replacement.
Between 40 and 71 % of patients suffering from TLS
develop a need for RRT [61]. The selection of RRT in
established TLS is briefly discussed in the next section.
RRT modality in critically ill patients with cancer
with AKI
Older studies on dialysis in patients with cancer were
discussed extensively in a previous review [10]. As indi-
cated in Table 1, various acute dialysis modalities are
used in critically ill cancer patients. Continuous dialysis
modalities are often preferred over intermittent therapies
to start RRT in hypotensive oliguric patients who require
vasopressors and large volumes of fluids. In an earlier
study in our unit, continuous renal replacement therapy
(CRRT) was initially used in 71.4 % vs 43.1 % of AKI pa-
tients with vs without hematological malignancies [9].
Many ICU centers start with CRRT and switch after-
wards to intermittent hemodialysis (IHD) when the
hemodynamic situation of the patient has stabilized.
A hybrid therapy called sustained low-efficiency dialysis
(SLED) or extended dialysis (EDD) has emerged as an al-
ternative to CRRT in the management of hemodynamically
unstable patients with AKI [62]. Salahudeen et al. [63]
retrospectively assessed 199 ICU cancer patients requiring
RRT. Most patients (62 %) had hematological cancers,
sepsis was present in 27 % of the cases, and 30-day mortal-
ity was 65 %. All patients received “continuous” SLED
(sustained low-efficiency extended dialysis). Although 75 %
of the patients were on vasopressors before dialysis initi-
ation, satisfactory ultrafiltration with acceptable hemo-
dynamic stability were achieved. This study was the first to
describe the technical characteristics of SLED in patients
with cancer in the ICU.
In a recent study with mainly solid cancer patients,
IHD was the initial RRT modality in 108 (72.5 %) pa-
tients [64]. The other 27.5 % were transferred to IHD
after 4.0 (2.0–7.0) days of CRRT. Thirty-eight (25.5 %)
patients were transferred from IHD to CRRT due to
hemodynamic instability. Fifty (34.1 %) of the patients
received both IHD and CRRT modalities during their
ICU stay. Overall, in these critically ill patients with can-
cer and AKI, IHD offered acceptable hemodynamic
stability and provided adequate metabolic control.
It is the author’s opinion that irrespective of the eti-
ology of AKI the choice of intermittent vs continuous
RRT should be based on the experience of the ICU and
nephrology team and the availability of therapies. When
both therapies are available, the indication of CRRT or
IHD is based on the patient’s neurologic, hemodynamic,
and catabolic status. Ideally, the therapy should be
tailored to the patient’s demands, which changes daily in
the critically ill. It is now accepted that more than one
therapy will be utilized for managing patients during the
course of AKI. Transitions from CRRT to IHD are com-
mon and reflect the changing needs of patients during
their AKI course. For instance, patients in the ICU may
initially start on CRRT when they are hemodynamically
unstable, transition to SLED–EDD when they improve,
and leave the ICU on IHD. Whenever possible, all dia-
lytic modalities should be utilized as indicated to best
support patient needs through their course.
CRRT should be preferred, however, for patients with
acute brain injury or other causes of increased intracra-
nial pressure of generalized brain edema.
There are some special considerations in the selection of
RRT in TLS. Given the potential ongoing liberation of sub-
stances from lysing cells in TLS, continuous therapies are
often preferred. However, IHD with the attendant rapid
clearance of potassium may be the modality of choice for
life-threatening hyperkalemia; this can then be followed by
a continuous therapy at high dialysate or replacement fluid
flow rates (of 3–4 l/h) to avoid rebound hyperkalemia and
provide ongoing dialytic therapy for TLS [65]. CRRT, such
as continuous venovenous hemofiltration (CVVHF), con-
tinuous venovenous hemodialysis (CVVHD), or combin-
ation therapy, may be preferable in the setting of severe
hyperphosphatemia. A high dialysate flow rate (3–4 l/h)
may be necessary to adequately maintain clearance in the
face of active liberation of cellular contents [65].
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Because acute peritoneal dialysis achieves inadequate
uric acid clearance, its routine use is not recommended
in TLS.
In recent years there has been great interest in novel
RRTs in myeloma cast nephropathy, the most frequent
form of AKI in multiple myeloma (MM) patients. AKI is
a frequent form of myeloma presentation and besides
the common causes of AKI some particular causes must
be considered in the extensive differential diagnosis,
such as hypercalcemia, glomerular amyloid or nonamy-
loid deposits, cast nephropathy, and infrequent kidney
infiltration by myeloma cells. Up to 90 % of cases of
severe AKI in MM are secondary to myeloma cast
nephropathy (for review see [14]).
Prompt institution of effective antimyeloma chemother-
apy remains the mainstay for the treatment of patients
with myeloma kidney, as response to chemotherapy is the
most important prognostic factor. New MM agents which
are well tolerated in patients with severe AKI (for instance,
bortezomib) have dramatically improved the prognosis of
MM patients with AKI at presentation, and recent studies
report a renal recovery rate of 30–60 % with an overall
survival of 21.5 months [66]. Effective suppression of the
proliferative clone by chemotherapy usually requires
several days to weeks following treatment initiation, and
extracorporeal removal of free light chains (FLCs) using
plasmapheresis or other dialytic techniques has been
reported as an adjunct to remove pathogenic serum FLCs
until the proliferative clone is controlled by chemotherapy
(for review see [67]).
Randomized controlled trials (RCTs) that have evalu-
ated the efficacy of plasma exchange as an adjunct to
chemotherapy argue against the use of this procedure in
the routine management of AKI associated with MM
[67]. By contrast, recent clinical data suggest that using
a dialyzer cartridge with pores of sufficient size to allow
the removal of FLCs using a newly developed polyflux®
high cut-off (HCO) 1100 protein-leaking dialyzer in con-
junction with effective chemotherapy can achieve sus-
tained reduction of serum FLC concentrations and may
potentially improve cast nephropathy [66]. Yadav et al.
[68] recently showed that an optimal approach, includ-
ing new MM agents in patients with AKI requiring RRT,
led to a 50 % rate of renal recovery. Encouraging was
the observation that patients who actually recovered had
a very good long-term prognosis characterized by an
overall survival of 64 months. Moreover, more than
95 % of patients remained dialysis independent until
death or end of follow-up. Serum FLC reduction at day
21 from baseline predicted the long-term GFR. Roughly
half of the patients who became dialysis-free were
dialyzed with either standard high-flux hemodialysis
(HF-HD) or extended high cut-off hemodialysis
(HCO-HD). Due to the small numbers in this study it
is impossible to make any firm conclusion whether
HCO-HD resulted in better outcomes compared with
HF-HD [68].
Unfortunately, there is at present no firm evidence
that HCO dialysis adds significant clinical benefits to
chemotherapy alone [67]. Thus, until convincing evi-
dence is available, the use of plasmapheresis and other
extracorporeal FLC removal techniques should be
limited to carefully selected patients within established re-
search protocols. A number of RCTs are currently on their
way: European Trial of Free Light Chain Removal
(EULITE) (controlled clinical trials ISRCTN45967602); and
Studies in Patients with Multiple Myeloma and Renal
Failure due to cast Nephropathy (MYRE) (ClinicalTrials.gov
NCT01208818).
Increased risk of CKD
AKI also increases the risk of incident CKD or acceler-
ates the progression of preexisting CKD (for recent re-
view see [69]).
Among long-term survivors of HSCT, the average preva-
lence of CKD in children and adults, based on studies
from 2007 onwards, was estimated to be 13 % [70].
A recent retrospective, longitudinal study of patients
who survived more than 10 years after myeloablative
allogeneic HSCT showed a cumulative increased inci-
dence of CKD which reached 34 % at 10 years [71]. Pa-
tients who did not have AKI did not develop CKD and
the adjusted hazard ratio increased with the severity of
AKI (based on AKIN classification). Patients are more
likely to develop CKD in the first year following HSCT
(15 %) than in subsequent years [71]. The increased risk
of CKD after AKI is particularly relevant in long-term
pediatric cancer survivors [72]. The precise mechanism
by which AKI accelerates CKD in humans is an area of
ongoing active research with the understanding of the
genesis of interstitial fibrosis as a central focus of study
(for recent reviews see [69]).
Recognizing that CKD is an important risk factor for
cardiovascular disease, progression to ESRD, infection,
hospitalization, and death, it is clear that preventing its
development by preventing AKI is also an important
goal among cancer patients.
Conclusions
Recent literature confirms that AKI requiring RRT is
more common in ICU patients with cancer than in those
without, and that ICU and hospital mortality rates are
high in patients with cancer and AKI, especially when
RRT is required. However, long-term survival is no
longer exceptional even in multiple organ failure cancer
patients requiring RRT. This improvement is probably
due to better ICU admission policies and triage of pa-
tients who should receive RRT, new and more efficient
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anticancer treatments, and better supportive care overall
during and after the ICU stay. Good collaboration and
open and honest communication between intensivists,
hemato-oncologists, and nephrologists is necessary in
order to further improve the prognosis of these very
complex patients and to guarantee that the degree of ad-
vanced life-supporting therapy remains proportional to
their expected long-term prognosis and quality of life
during their entire ICU stay.
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